Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,434 Mln
Revenue (TTM)
$250 Mln
Net Profit (TTM)
$0 Mln
ROE
0.2 %
ROCE
-- %
P/E Ratio
42.4
P/B Ratio
6.2
Industry P/E
--
EV/EBITDA
24.8
Div. Yield
0.8 %
Debt to Equity
0.5
Book Value
$17.1
EPS
$2.5
Face value
--
Shares outstanding
22,778,363
CFO
$222.43 Mln
EBITDA
$240.18 Mln
Net Profit
$179.19 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
LeMaitre Vascular (LMAT)
| 33.8 | 0.3 | 33.8 | 27.4 | 28.2 | 17.4 | 21.3 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
LeMaitre Vascular (LMAT)
| -12.0 | 61.7 | 23.3 | -8.4 | 24.0 | 12.7 | 52.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
LeMaitre Vascular (LMAT)
|
108.5 | 2,434.3 | 249.6 | 57.7 | 32.2 | 15.8 | 42.4 | 6.2 |
| 7.9 | 5,388.2 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 278.3 | 7,510.1 | 2,583.2 | 759.9 | 25.2 | 10.8 | 10 | 1.0 | |
| 36.8 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 112.8 | 6,549.6 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.0 | |
| 76.1 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.6 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 330.4 | 12,964.3 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.9 | 9.0 | |
| 117.8 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,716.9 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.5 | 2.6 |
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are... cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts. Address: 63 Second Avenue, Burlington, MA, United States, 01803 Read more
Chairman & CEO
Mr. George W. LeMaitre
Chairman & CEO
Mr. George W. LeMaitre
Headquarters
Burlington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of LeMaitre Vascular Inc (LMAT) is $108.49 (NASDAQ) as of 02-Apr-2026 16:00 EDT. LeMaitre Vascular Inc (LMAT) has given a return of 28.22% in the last 3 years.
The P/E ratio of LeMaitre Vascular Inc (LMAT) is 42.41 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
32.26
|
4.73
|
|
2024
|
47.92
|
6.26
|
|
2023
|
42.34
|
4.28
|
|
2022
|
49.59
|
3.82
|
|
2021
|
41.33
|
4.38
|
The 52-week high and low of LeMaitre Vascular Inc (LMAT) are Rs 115.33 and Rs 71.42 as of 04-Apr-2026.
LeMaitre Vascular Inc (LMAT) has a market capitalisation of $ 2,434 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in LeMaitre Vascular Inc (LMAT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.26
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.